Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.8M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$131M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| AULT MILTON C III | Aug 6, 2024 | Buy | 75 | $2.75 | $210 |
| AULT MILTON C III | Jul 31, 2024 | Buy | 25 | $3.7368 | $93 |
| AULT MILTON C III | Apr 19, 2024 | Buy | 1,000 | $0.6882 | $690 |
| AULT MILTON C III | Apr 1, 2024 | Buy | 334 | $0.9109 | $300 |
| AULT MILTON C III | Mar 26, 2024 | Buy | 780,000 | $0 | $0 |
| AULT MILTON C III | Mar 26, 2024 | Buy | 780 | $1000 | $780,000 |
| AULT MILTON C III | Jan 31, 2024 | Buy | 1,220,000 | $0 | $0 |
| AULT MILTON C III | Jan 31, 2024 | Buy | 1,220 | $1000 | $1.2M |
| AULT MILTON C III | Jan 5, 2024 | Buy | 2,000 | $1.0635 | $2,100 |
| AULT MILTON C III | Jan 5, 2024 | Buy | 5,000 | $1.0185 | $5,100 |
| McGrath Lynne Fahey | Dec 26, 2023 | Sell | 666 | $0.881 | $590 |
| AULT MILTON C III | Dec 26, 2023 | Buy | 500 | $0.9 | $450 |
| AULT MILTON C III | Dec 22, 2023 | Buy | 200 | $0.9242 | $180 |
| Katzoff David J | Sep 26, 2023 | Buy | 53,000 | $0.1931 | $10,000 |
| AULT MILTON C III | May 24, 2023 | Buy | 18,000 | $0.5947 | $11,000 |
| Jackman Stephan | Apr 28, 2023 | Buy | 37,000 | $0.5405 | $20,000 |
| McGrath Lynne Fahey | Mar 22, 2023 | Buy | 10,000 | $0.435 | $4,400 |
| AULT MILTON C III | Mar 17, 2023 | Buy | 5,000 | $0.4298 | $2,100 |
| AULT MILTON C III | Mar 16, 2023 | Buy | 4,000 | $0.5014 | $2,000 |
| AULT MILTON C III | Feb 15, 2023 | Buy | 1,000 | $0.5973 | $600 |
| AULT MILTON C III | Dec 28, 2022 | Buy | 3,100 | $0.5629 | $1,700 |
| AULT MILTON C III | Dec 27, 2022 | Buy | 900 | $0.591 | $530 |
| AULT MILTON C III | Dec 21, 2022 | Buy | 5,000 | $0.8099 | $4,000 |
| AULT MILTON C III | Dec 19, 2022 | Buy | 20,000 | $0.8179 | $16,000 |
| AULT MILTON C III | Dec 19, 2022 | Buy | 3,000 | $0.8184 | $2,500 |
| AULT MILTON C III | Nov 18, 2022 | Buy | 1,000 | $1.289 | $1,300 |
What's the latest insider transaction for Alzamend Neuro?
The most recent insider transaction for Alzamend Neuro was conducted by AULT MILTON C III, who sold 75 shares on August 6, 2024 at a price of $2.75 per share.
Which insider bought the most ALZN stock over the last two years?
AULT MILTON C III has bought the most ALZN stock in the last 2 years, with a total value of $2.1M.
Which insider has sold the most ALZN stock over the last two years?
McGrath Lynne Fahey has sold the most ALZN stock in the last 2 years, with a total value of $590.
What is the total value of insider transactions for Alzamend Neuro (ALZN) in the last 2 years?
According to our estimates, the total value of insider transactions for Alzamend Neuro in the last 2 years is positive, amounting to $2.1M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
How do insider transactions over the last 2 years reflect on Alzamend Neuro's market confidence?
Over the last 2 years, insider transactions for Alzamend Neuro have predominantly involved purchasing shares, indicating a strong confidence among insiders in the company's future prospects. This trend of more purchases than sales could be a positive signal to potential investors about the insiders' view on the company's valuation and growth potential.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
